英捷信医疗完成数千万元人民币A+轮融资，加速国际化布局

Core Viewpoint - Shanghai Ingezhixin Medical Technology Co., Ltd. has successfully completed a multi-million RMB A+ round financing, which will be used to expand its global high-quality production capacity and marketing teams [1] Group 1: Financing Details - The A+ round financing was exclusively invested by Yida Capital, with Haoyue Capital serving as the exclusive financial advisor [1] - The funds raised will support the construction of a global high-quality standard production capacity system [1] Group 2: Company Profile - Ingezhixin Medical is recognized as a national high-tech enterprise focused on independent innovation [1] - The company has established a complete independent intellectual property system through precision manufacturing processes [1] Group 3: Market Position and Products - The company currently provides services to dozens of large domestic and international biopharmaceutical companies [1] - Its product offerings cover multiple fields, including GLP-1 drugs, insulin, and growth hormones, with a leading customer coverage in the domestic GLP-1 sector [1] - Ingezhixin Medical has successfully expanded into multiple overseas markets, demonstrating significant global layout effects [1]